BM
$1.30
+0.03
(+2.36%)
As of Oct 5, 2026, 4:18 PM EDT
Price history
Biomea Fusion (BMEA) is trading up at $1.30 (+2.36%), as of the latest quote. It operates in the Health Care sector.
IPO: April 16, 2021 · $17.00 offering · NASDAQ · View IPO details →
Biomea Fusion net income history (FY2019–FY2025)
Net income
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Operating income | −$1.20M | −$5.33M | −$41.7M | −$83.6M | −$126.1M | −$144.1M | −$83.5M |
| Net income | −$1.20M | −$5.32M | −$41.6M | −$81.8M | −$117.3M | −$138.4M | −$61.8M |
| EPS (diluted) | −$0.20 | −$0.51 | −$1.74 | −$2.80 | −$3.44 | −$3.83 | −$1.18 |
| Balance sheet | |||||||
| Cash and equivalents | $239.0K | $61.7M | $145.7M | $111.9M | $176.9M | $58.3M | $55.8M |
| Total assets | — | $62.5M | $185.7M | $129.3M | $199.9M | $79.9M | $58.6M |
| Total liabilities | — | $1.62M | $6.92M | $20.8M | $30.7M | $28.4M | $29.0M |
| Shareholders' equity | −$21.0K | $5.17M | $178.8M | $108.5M | $169.2M | $51.6M | $29.6M |
| Cash flow | |||||||
| Operating cash flow | −$1.28M | −$4.46M | −$35.4M | −$62.4M | −$96.6M | −$119.9M | −$70.4M |
| Capital expenditure | — | $51.0K | $3.17M | $1.03M | $3.37M | $362.0K | — |
| Free cash flow | — | −$4.51M | −$38.6M | −$63.4M | −$100.0M | −$120.3M | — |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$34.0M | −$30.1M | −$29.7M | −$21.3M | −$20.8M | −$11.7M | −$12.8M | −$12.8M |
| Net income | −$32.8M | −$29.3M | −$29.3M | −$20.7M | −$16.4M | $4.61M | −$12.4M | −$8.33M |
| EPS (diluted) | −$0.91 | −$0.80 | −$0.80 | −$0.51 | −$0.27 | $0.40 | −$0.17 | −$0.12 |
| Balance sheet | ||||||||
| Cash and equivalents | $88.0M | $58.3M | $35.9M | $56.2M | $46.6M | $55.8M | $44.7M | $34.8M |
| Total assets | $110.4M | $79.9M | $55.1M | $73.2M | $55.2M | $58.6M | $46.4M | $36.9M |
| Total liabilities | $34.4M | $28.4M | $26.3M | $45.7M | $39.6M | $29.0M | $27.7M | $24.7M |
| Shareholders' equity | $76.0M | $51.6M | $28.7M | $27.5M | $15.6M | $29.6M | $18.7M | $12.1M |
| Cash flow | ||||||||
| Operating cash flow | −$25.2M | −$30.0M | −$25.7M | −$19.2M | −$11.6M | −$13.9M | −$11.7M | −$10.0M |
| Capital expenditure | $186.0K | $82.0K | $0 | $0 | $0 | — | — | — |
| Free cash flow | −$25.4M | −$30.1M | −$25.7M | −$19.2M | −$11.6M | — | — | — |
From Biomea Fusion's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Biomea Fusion
- Headquarters
- San Carlos, California From SEC filings, Oct 2026
Recent News (2)
-
Biomea Fusion Announces Termination of Proposed Public Offering of Securities SAN CARLOS, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has term…
-
Biomea Fusion Announces Proposed Public Offering of Securities SAN CARLOS, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwri…
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International